# RRPV Solicitation Summary: COVID-19 Monoclonal Antibody Therapeutics for Treatment

Canonical: https://abierto.us/opportunities/rpp2403treatment

- Solicitation number: RPP-24-03-Treatment
- Notice type: Special notice
- Status: Closed. Deadline was April 8, 2024 at 1:00 PM EDT
- Department: Department of Health and Human Services
- Agency: Office of Assistant Secretary for Preparedness and Response
- Contracting office: Barda - Aspr / Daappo / Barda DCMA (75A501)
- NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code: AN42 Health R&D Services; Health Care - Other; Applied Research
- Place of performance: Washington, District of Columbia
- County: District of Columbia (FIPS 11001). https://abierto.us/counties/district-of-columbia-dc-11001
- City: Washington. https://abierto.us/cities/washington-dc-1150000
- First posted: February 21, 2024
- Last posted: February 21, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/6adaaeb52894454f9ac4e5909dd1f6c7/view

## Description

This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of Biomedical Advanced Research and Development Authority (BARDA) entitled "COVID-19 Monoclonal Antibody Therapeutics for Treatment". The full RPP and information on joining the consortium can be accessed through the RRPV website www.rrpv.org. Thank you for your interest in this requirement.

## Publications

- February 21, 2024: Special notice, due April 8, 2024 at 1:00 PM EDT. Notice 6adaaeb52894454f9ac4e5909dd1f6c7. https://sam.gov/workspace/contract/opp/6adaaeb52894454f9ac4e5909dd1f6c7/view

## Points of contact

- Rebecca Harmon, rebecca.harmon@ati.org

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/rpp2403treatment.